Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 9/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Detomidine SCHEMBL2626815 | 0.80 | ADRA1D (0.58) | ADRA1DADRA2AADRA1AADRA2BADRA2C | |
| Detomidine SCHEMBL29833001 | 0.80 | ADRA1D (0.58) | ADRA1DADRA2AADRA1AADRA2BADRA2C | |
| Detomidine SCHEMBL29371271 | 0.79 | ADRA1D (0.59) | ADRA1DADRA2AADRA1AADRA2BADRA2C | |
| Detomidine SCHEMBL21624995 | 0.78 | ADRA1D (0.55) | ADRA1DADRA2AADRA1AADRA2BADRA2C | |
| Detomidine SCHEMBL22999498 | 0.77 | ADRA1D (0.54) | ADRA1DADRA2AADRA1AADRA2BADRA2C | |
| SCHEMBL31253907 | 0.76 | ADRA1D (0.50) | ADRA1DADRA2AADRA1AADRA2BADRA2C | |
| SCHEMBL5201429 | 0.73 | ADRA1A (0.48) | ADRA1DADRA2AADRA1AADRA2BADRA2C | |
| SCHEMBL2626816 | 0.72 | ADRA1D (0.55) | ADRA1DADRA2AADRA1AADRA2BADRA2C | |
| SCHEMBL26960858 | 0.72 | ADRA1D (0.51) | ADRA1DADRA2AADRA1AADRA2BADRA2C | |
| SCHEMBL23646734 | 0.71 | ALDH1A1 (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323929-A1 | Purified Detomidine, Process of Preparing and Methods of Use | CLEXIO BIOSCIENCES LTD (IL) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323929-A1 | Purified Detomidine, Process of Preparing and Methods of Use | QDPR, DCTD, NEFM | ADRA1D 529/4885ADRA2A 549/4885ADRA1A 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.